



Press release from Emotra AB (publ)

Göteborg, June 9, 2014

A crucial Emotra development project has been completed

In collaboration with Prevas in Linköping, Emotra has now completed all of the important steps in the development of software that will automate most manual analysis tasks. This project was originally planned to last until the end of 2014, but we have already made so much progress that approximately 90 percent of all manual analysis work can be eliminated. This, in turn, increases the Company's analytical capacity tenfold.

Emotra has previously notified that the Company has signed an agreement with an experienced consultancy firm for the development of software to automate the greater part of our manual test analysis effort. The fact that this development project has been completed ahead of schedule means that we will be able to carry out the analyses of our ongoing multi-clinical trials faster and more efficiently. However, the most significant advantage of this new software is that it solves our long-term requirement for greater analytical capacity. Being able to meet a growing demand for tests using EDOR has always been a high-priority goal for our business.

Another goal of this development agreement is to create a method for the efficient and secure transfer, in both directions, of large data volumes between clinics and Emotra. Furthermore, this collaboration aims to develop a high-capacity database to store all essential parameters, concerning both the patients that have been tested and about the factors that assessment conclusions have been based on. One of the advantages of creating a large database of this kind is that it will enable future comparative studies between different patient groups as well as between patients that have received different assessments or treatments.

Our continued efforts during the next 12 months will increasingly focus on creating a global communication platform for large quantities of data, enabling different users to get access to their own documentation for retrospective studies and on achieving further simplifications and improvements. Quite simply, our goal with this software development is to facilitate future suicide-prevention research.

"At present, Emotra is in the middle of a very dynamic phase, and its activities involve an increasing number of clinical centres. In order to minimise the financial risks, all work is carried out within a small organisation and as cost-effectively as possible. When international, scientific support for EDOR from these clinics has grown sufficiently strong, we will launch the method in Europe. Through this successfully completed development project we now know that we can meet great demand of tests using EDOR," says Claes Holmberg, CEO of Emotra AB.

For further information, please contact:

Claes Holmberg, CEO

Telephone: 046 708 25 45 47

E-mail: claes@emotra.se

Emotra AB is listed on AktieTorget, and the Company has developed a method – EDOR – of detecting depressed patients who are at risk of committing suicide. Altogether, more than 1,000 patients have been tested and followed up. EDOR has shown a reliability rate of up to 97%. In other words, Emotra's method can determine, with 97% certainty, if a person runs a significantly higher risk of suicide attempt, facilitating decisions about where special suicide prevention measures are needed. EDOR helps the right patients get the care they need.